Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
A phase 3 trial of 177Lu-TLX250 in renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.
Overview
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC is a phase 3 interventional study registered as NCT07197580 by Telix Pharmaceuticals (Innovations) Pty Limited, with 40 participants planned, started 2026-03-25 and due to reach its primary completion in 2027-08-31. Interventions recorded: 177Lu-TLX250.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma, Lutetium-177 and the tag pipeline.
- AgentZirconium-89 girentuximab
Shares CAIX (carbonic anhydrase IX), Renal cell carcinoma and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Lutetium-177 and the tag pipeline.
- TrialAn Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Shares Lutetium-177 and the tag pipeline.
- TrialA Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Shares Lutetium-177 and the tag pipeline.
- TrialStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Shares Lutetium-177 and the tag pipeline.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Lutetium-177 and the tag pipeline.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Lutetium-177 and the tag pipeline.